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Abstract
Background: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a
clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive
disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness
or lack of access to care. This study seeks to assess the impact of the 1st lockdown – pre-, during and post – in
adults with a recent history of MDD across multiple centres.
Methods: This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study
examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and
passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and
had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed
models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration.
Results: In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before
the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem
changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in
minutes) decreased significantly between during- and post- lockdown (− 12.16; 95% CI − 18.39 to − 5.92; p < 0.001).
We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic
showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown
(interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not.
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Conclusions: We identified changes in depressive symptoms and sleep duration over the course of lockdown,
some of which varied according to whether participants were experiencing clinically relevant depressive symptoms
shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a
significant worsening in symptoms during the first months of the Covid − 19 pandemic.
Keywords: Remote measurement technology, Major depressive disorder, Mobile health
Background
On the 31st December 2019, the World Health Organ-
isation (WHO) documented reports of a cluster of cases
of pneumonia of unknown origin in Wuhan, China [1].
The cause was later identified as a novel severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2), which
caused a clinical illness, Covid-19 [2]. Within weeks of
the initial outbreak, the total number of cases and deaths
had exceeded those of severe acute respiratory syndrome
outbreak in 2003 [3]. In March 2020, a global pandemic
was declared by the WHO due to the exponential in-
crease in diagnosed cases and deaths, with countries
across Europe implementing national lockdowns to re-
duce the risk of spread and infection [4].
The ongoing Covid-19 pandemic is predicted to have
severe negative global mental health consequences [5, 6],
with a review of stressors indicating that quarantine dur-
ation, infection fears, frustration, boredom, inadequate
information, financial loss, loss of sleep and stigma being
the main drivers [7]. The pandemic has disrupted or
halted critical mental health services in 93% of countries
worldwide, while the demand for mental health care is
increasing, according to a recent WHO survey [8]. There
have been urgent calls to examine the mental health
consequences of Covid-19 at an international level, using
high-quality data and robust analysis techniques [9–11].
Gaining a clear indication of population impacts of the
pandemic on mental health has been challenging [6].
Pre-existing population studies, which have explicit sam-
pling frames and longitudinal data pre-dating the pan-
demic, have demonstrated an increase in symptoms of
distress within the general population [6, 12]. And in the
early stages of the pandemic this was dominated by
symptoms of anxiety [12], with symptoms of distress
most frequent in young adults [6]. In addition, one
population study found sleep to be negatively impacted
by the pandemic, with female participants reporting
more sleep loss than male participants [13].
A less studied issue has been the impact of public
health measures, such as lockdown, on individuals with
pre-existing mental disorders who may have less access
to care and support services [8]. Adults diagnosed with
major depressive disorder (MDD) and experiencing a
current episode of depression are particularly susceptible
to the challenges raised by lockdown, such as disrupted
sleep [14], reduced sociability [15] and changes in
mood/self-esteem [16]. Therefore, it is important to
understand the trajectories of change in those experien-
cing a current episode of depression and how these out-
comes are impacted by the pandemic.
Across Europe, smartphone ownership and use is high
(estimated 76% of adults across Europe [17]), which pro-
vides a ready means for accurate and ongoing data col-
lection using remote measurement technology (RMT)
[18–20]. RMT data collection methods are inexpensive,
can gather data in real-time, and crucially considering
infection risk, do not require face-to-face contact be-
tween the research team and participants. RMT may
provide a solution to the need for surveillance at the
population level passively, without the need for intrusive
study protocols, or continual engagement. This may lead
to richer, more objective and holistic characterisation of
behaviours and physiology as a result of the Covid-19
pandemic.
Remote Assessment of Disease and Relapse in individ-
uals with Major Depressive Disorder (RADAR-MDD) is
an ongoing study forming a component of the RADAR-
Central Nervous System consortium [21]. Participants
with MDD from the UK, Spain and The Netherlands
were invited to provide longitudinal data via ubiquitous,
commercially-available RMT (i.e. phones and activity
trackers) [18]. The high-frequency information collected
passively includes detail on participants’ sleep quality/
patterns, physical activity, stress, mood, self-esteem, so-
ciability, speech patterns, and cognitive function [18]. In
addition to passive data collection, self-reported eco-
logical momentary assessment data was also collected.
This included assessments focusing on depression,
speech, self-esteem, and cognitive function. The study
provides an opportunity to explore the impact of the
pandemic on individuals with a MDD diagnosis and
their changes in depressive symptoms across Europe. A
strength of RADAR-CNS is the ability to directly com-
pare results gathered during- and post- lockdown with
previously collected pre-lockdown baseline data.
The potential impact of the pandemic on individuals
with mental disorders has been recognised as one of a
triad of key current global mental health challenges [22].
Relatively high rates of depression have been reported by
a number of countries [23], this adding to the existing
global burden of depression [24]. However, tackling this
in its entirety demands a greater understanding of the
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true impact of Covid-19 for those living with pre-
existing mental disorders. We therefore aimed to investi-
gate the impact of the 1st global lockdown on adults
with a recent history of MDD, through the following ob-
jectives: 1) To investigate changes in depressive symp-
toms, self-esteem and sleep duration pre-, during- and
post-lockdown in the period from 1st December 2019 to
1st September 2020; and 2) To investigate whether these
changes over time varied according to whether partici-
pants were experiencing a depressive episode shortly be-
fore the pandemic.
Method
Data source and participants
This study uses data collected between 1st December
2019 and 1st September 2020 (9 months of available
data) from the RADAR-MDD project, a multi-centre co-
hort, examining the use of RMT in monitoring MDD
[18]. Participants were required to meet the following
eligibility criteria: 1) DSM-5 diagnostic criteria for diag-
nosis of non-psychotic MDD in the last 2 years, 2) recur-
rent MDD (lifetime history of at least 2 episodes of
depression, 3) willingness and ability to complete self-
reported assessment via smartphone, 4) provide in-
formed consent, 5) own an Android smartphone, or will-
ing to use an Android smartphone provided by the
research team, 6) aged 18 years or over, and 7) fluent in
English, Spanish, Catalan or Dutch. The study protocol
for RADAR-MDD has been previously reported [18].
The data collected via RADAR-MDD project uses
RADAR-base, which is an open source platform de-
signed to leverage data from wearables and mobile tech-
nologies [21]. RADAR-base provides both passive and
active data collection via two applications – active and
passive. The passive app collects real time monitoring of
movement, location, audio and app usage [21]. The ac-
tive app collects self-reported user questionnaires. Data
from both apps are streamed in real-time to project
servers. It is important to note that RADAR-base does
not provide a feedback loop to the participant or any
clinicians.
In total, 623 participants met the eligibility criteria and
were recruited between November 2017 and June 2020
across three European countries: United Kingdom (n =
350; 56.2%), Spain (n = 155; 24.9%) and The Netherlands
(n = 118; 18.4%). Participants in the UK and The
Netherlands were recruited from community samples in-
cluding individuals from existing studies on depression
and using local clinical services. All participants re-
cruited for this study had pre-existing major depressive
disorder, and all recruitment sites utilised the same eligi-
bility criteria for entry into the study. The Netherlands
also recruited through advertisements in general prac-
tices and psychologist practices, newspaper
advertisements and through Hersenonderzoek.nl
(https://hersenonderzoek.nl). Spanish participants were
recruited from a clinical sample of individuals seeking
help for a mental health condition.
Each participant was asked to wear a wrist-worn activ-
ity tracker (FitBit Charge 2 or 3) and install the active
and passive RADAR-base applications onto their smart-
phones (see [18, 21] for further details). The project was
developed using co-design and in partnership with a Pa-
tient Advisory Group. Project apps were used to collect
data passively from existing smartphone sensors, and to
deliver questionnaires, cognitive tasks, and speech as-
sessments. The wrist-worn activity tracker and project
apps collected data on participants’ sleep, physical activ-
ity, stress, mood, self-esteem, sociability, speech patterns,
and cognitive function.
The RADAR-MDD project is currently on-going and
final data collection is expected in March 2021. Partici-
pants were excluded from the current study if they had
withdrawn from the RADAR-MDD project at any time
(n = 78; 12.5%), enrolled in RADAR-MDD after the 1st
December 2019 (n = 200; 32.1%), had not completed a
self-reported Patient Health Questionnaire (PHQ) in De-
cember 2019, or were missing basic demographics at
baseline (n = 93; 14.9%). A total of 252 (40.5%) partici-
pants remained after exclusions and their data was used
for analysis.
The RADAR-MDD project received ethical approval in
the United Kingdom from the Camberwell St Giles Re-
search Ethics Committee (REC reference: 17/LO/1154);
and Spain from the CEIC Fundació Sant Joan de Déu
(CI reference: PIC-128-17) and in The Netherlands from
the Medische Ethische Toetsingscommissie VUmc
(METc VUmc registratienummer: 2018.012 –
NL63557.029.17). The research was undertaken in ac-
cordance with the Declaration of Helsinki, and all partic-
ipants provided informed consent to participate.
Measures and features
The RADAR-MDD project collects a range of validated
measures from participants at different timepoints (see
further [18] information) using the RADAR-base active
app [25]. RADAR-base sends automatic survey invita-
tions (email and in-app push notification).
Depressive symptoms
The Patient Health Questionnaire (PHQ-8 [26];) was de-
livered every 2 weeks via the project app. The PHQ-8 is
an 8-item self-report questionnaire which measures the
frequency of depressive symptoms over the preceding 2-
week period. Each item is rated on a scale of 0–3, produ-
cing a range of total scores from 0 to 24. The PHQ-8
has good validity, reliability, sensitivity, and specificity in
the general population [26]. In this study, a cut-off score
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of 10 or more is defined as a case of clinically relevant
depressive symptoms (hereafter ‘depression’) [26].
Self-esteem
The Rosenberg Self-Esteem Scale (RSES [27];) was deliv-
ered every 2 weeks via the project app alongside the
PHQ-8. The RSES is a 10-item self-report instrument
for evaluating individual self-esteem [27–29]. Each item
is rated on a scale of 1–3 (half the questions are reverse
scored), producing a range of scores from 0 to 30. Scores
between 15 and 25 are within normal range, with scores
below 15 suggesting low self-esteem [27].
Sleep duration
Participants enrolled in the RADAR-MDD project were
asked to wear a wrist-worn activity tracker (FitBit
Charge 2 or 3) over the study duration as much as pos-
sible, including when sleeping. The device collected pa-
rameters on heart rate and sleep duration. In this study,
total sleeping minutes, as computed by the FitBit Charge
2 or 3, was extracted for each participant for each day
and a daily feature was calculated to represent the
amount slept for each 24-h period. Total sleep duration
was calculated between 8:00 pm (20:00) as the starting
time point and 11:00 am (11:00) as the finishing time-
point (following a procedure reported previously [30]).
Where no data was found due to the participant not
wearing the device, no features were computed for that
day.
Data analysis
Socio-demographic characteristics were summarised
using frequencies and unweighted percentages or me-
dians with interquartile ranges (IQR) for the overall
sample and for each country individually. Outcome vari-
ables (depressive symptoms, self-esteem and sleep dur-
ation were then summarised across three timepoints:
pre-, during- and post-lockdown (defined as restriction
easing in each country). A mean value was computed for
depressive symptoms (PHQ-8 score), self-esteem (RSES
score) and sleep duration (minutes) for each participant
within each of these timepoints.
The following dates were used to define these time-
points [31]:
 United Kingdom: lockdown: 23/03/2020 and easing
restrictions: 11/05/2020;
 Spain: lockdown: 14/03/2020 and easing restrictions:
02/05/2020;
 The Netherlands: lockdown: 17/03/2020 and easing
restrictions: 11/05/2020.
Changes in the mean total score of each outcome vari-
able over these timepoints were analysed using linear
mixed models for repeated measures. Linear mixed
models are a generalisation of linear regression which
permit modelling of repeated measures data by incorp-
orating a random effect of ‘participant’. First, we investi-
gated the overall changes in each outcome variable using
timepoint (pre-, during- and post-lockdown) as the ex-
posure variable. We then added pre-pandemic depres-
sion caseness into each model as a second exposure
variable, including an interaction term between time-
point and depression caseness, to investigate whether
rate of change in the outcome variables over time varied
according to depression caseness. Pre-pandemic depres-
sion caseness (denoted as: no depression, depression)
was defined as a participant scoring 10 or more on the
PHQ-8 during December 2019. This was used to define
clinically relevant depressive symptoms shortly before
the pandemic.
We used post-estimation commands to further ex-
plore the associations identified in mixed modelling.
Models were fitted using Maximum Likelihood Esti-
mation and an unstructured residual-error covariance
matrix. Mixed models can produce valid estimates
even when data is not missing completely at random,
without the need for further missing data techniques
like multiple imputation [32].
A participant could have completed a maximum of 18
PHQ-8/RSES self-report questionnaires during the ana-
lysis timepoints. RMT offers a unique ability to monitor
and track participants, however due to the frequency of
data collection, technical issues and daily life, missing
data is inevitable, and further information relating to this
is presented in Supplement A. Statistical significance
was defined as a p-value of less than 0.05. Data process-
ing was performed in Python version 3.5. All analyses
were performed using STATA MP 16.1.
Results
Socio-demographic characteristics at baseline
The majority of the sample was female (n = 188; 74.6%),
had clinically relevant depressive symptoms shortly be-
fore the pandemic (n = 121, 48.0%), was cohabiting or
married (n = 138; 54.8%) and was on medication for
management of depression (n = 166; 65.9%) at baseline
(see Table 1).
Depressive symptom trajectories
Overall, mean depressive symptoms remained stable be-
tween pre- and during-lockdown (estimated mean score
difference: -0.18; CI: − 0.61 to 0.24, p = 0.339) and be-
tween during- and post-lockdown (estimated mean score
difference: -0.03; CI: − 0.42 to 0.36, p = 0.882) (Table 2).
We then added an interaction term between depres-
sion caseness and timepoint to investigate whether these
trajectories varied according to depression caseness.
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Table 1 Cohort characteristics at baseline (n = 252) stratified by country
Variable Overall (n =
252)
United Kingdom (n = 140;
55.6%)
Spain
(n = 70; 27.8%)
The Netherlands (n = 42;
16.7%)
Sex
Male 64 (25.4) 30 (21.3) 24 (34.3) 10 (23.8)
Female 188 (74.6) 110 (78.6) 46 (65.7) 32 (76.2)
Marital status
Single 75 (29.8) 40 (28.6) 10 (14.3) 25 (59.5)
Married/cohabiting 138 (54.8) 82 (58.6) 43 (61.4) 13 (30.9)
Divorced/Separated/Widowed 39 (15.5) 18 (12.9) 17 (24.3) 4 (9.5)
Employment
Employed 115 (45.6) 66 (47.1) 28 (40.0) 21 (50.0)
Retired 64 (25.4) 35 (25.0) 25 (35.7) 4 (9.5)
Student 23 (9.1) 12 (8.8) 1 (1.4) 10 (23.8)
Unemployed 26 (10.3) 14 (10.0) 9 (12.9) 3 (7.1)
Other 24 (9.5) 13 (9.3) 7 (10.0) 4 (9.5)
Age (in years)
< 25 16 (6.4) 7 (5.0) – 9 (21.4)
25–34 35 (13.9) 22 (15.7) 2 (2.9) 11 (26.2)
35–44 38 (15.1) 22 (15.7) 12 (17.1) 4 (9.5)
45–54 42 (16.7) 19 (13.6) 18 (25.7) 5 (11.9)
55–64 81 (32.2) 44 (31.4) 28 (40.0) 9 (21.4)
65> 40 (15.9) 26 (18.6) 10 (14.3) 4 (9.5)
Medication for Depression
No 48 (19.1) 36 (25.7) 2 (2.9) 10 (23.8)
Yes 166 (65.9) 80 (57.1) 65 (92.9) 21 (50.0)
Not reported 38 (15.1) 24 (17.1) 3 (4.3) 11 (26.2)
Depressiona (December 2019)
No Depression 131 (52.0) 87 (62.1) 28 (40.0) 16 (38.10)
Depression 121 (48.0) 53 (37.9) 42 (60.0) 26 (61.9)
Length of education (in years) (mean, SD)b 15.9 (6.5) 16.5 (5.5) 12.5 (4.9) 19.3 (8.9)
Length of time in study in days [median,
IQR]b
253 (124 to 327) 285.5 (186.5 to 435) 257.5 (158 to
306)
109.5 (44 to 170)
aAs measured by the Patient Health Questionnaire [26]. Depression defined as scoring 10 or more. bUp to 1st December 2019
Table 2 Estimated overall differences in each outcome variable between each timepoint. Results stratified by country are available
from the corresponding author
Estimated difference between pre- and during- lockdown
(95% CI, p-value)




-0.18 (− 0.61 to 0.24; p = 0.339) -0.03 (− 0.42 to 0.36; p = 0.882)
Mean RSES
score
-0.06 (− 0.22 to 0.10; p = 0.445) 0.07 (− 0.08 to 0.22; p = 0.381)
Mean sleep
duration
-0.01 (− 5.55 to 5.56; p = 1.000) -12.16 (− 18.39 to − 5.92; p < 0.001)
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Perhaps unsurprisingly, those with pre-pandemic depres-
sion reported more depressive symptoms at all three
timepoints (Table 3). However, there was also some evi-
dence for an interaction between depression caseness
and timepoint in predicting course of depressive symp-
toms between pre- and during-lockdown (p = 0.047;
Table 3).
We further investigated this using post-estimation
commands and found very weak evidence that the de-
pressed group showed a decrease in depressive symp-
toms between pre- and during-lockdown (estimated
mean score: -0.61; CI: − 1.23 to 0.01; p = 0.051), whereas
the non-depressed group remained stable (estimated
mean score: 0.24; CI: − 0.33 to 0.83, p = 0.409) (Fig. 1).
Self-esteem trajectories
Overall, mean self-esteem score remained stable between
pre- and during-lockdown (estimated mean score differ-
ence: -0.06; CI: − 0.22 to 0.10, p = 0.445) and between
during- and post-lockdown (estimated mean score dif-
ference: 0.07; CI: − 0.08 to 0.22, p = 0.381) (Table 2).
We then added an interaction term between depres-
sion caseness and timepoint to investigate whether these
trajectories varied according to depression caseness.
Those with pre-pandemic depression reported lower
self-esteem scores throughout the pandemic than those
without depression (Table 3). There was also some
evidence for an interaction between depression caseness
and timepoint in predicting course of self-esteem be-
tween pre- and during-lockdown (p = 0.045; Table 3).
We further investigated this using post-estimation
commands and found evidence that the depressed group
showed reducing self-esteem scores between pre- and
during-lockdown (estimated mean score: -0.24; CI: −
0.47 to 0.01; p = 0.048), whereas the non-depressed
group remained stable (estimated mean score: 0.09; CI:
− 0.13 to 0.32, p = 0.409) (Fig. 2).
Sleep duration trajectories
Overall, mean sleep duration remained stable between
pre- and during-lockdown (estimated mean duration dif-
ference: -0.01; CI: 5.55 to 5.56, p = 1.000). However, be-
tween during- and post-lockdown there was evidence of
a significant decrease in mean sleep duration (estimated
mean duration difference: -12.16; CI: − 18.39 to − 5.92,
p < 0.001) (Table 2).
We then added an interaction term between depres-
sion caseness and timepoint to investigate whether these
trajectories varied according to depression caseness.
Those with pre-pandemic depression reported shorter
sleep durations during- and post-lockdown relative to
those without (Table 3). There was also evidence for an
interaction between depression caseness and timepoint
Table 3 Estimated difference in each outcome variable between no depression and depression (in December 2019) at each
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in predicting course of mean sleep duration between
pre- and during-lockdown (p < 0.001; Table 3).
We further investigated this using post-estimation
commands and found strong evidence that the depressed
group showed significant decreases in mean sleep dur-
ation between pre- and during-lockdown (estimated
mean duration difference: -11.64; CI: − 19.33 to − 3.95;
p = 0.003), whereas the non-depressed group signifi-
cantly increased mean sleep duration (estimated mean
sleep duration difference: 10.85; CI: 3.43 to 18.27; p =
0.004) (Fig. 3). However, the interaction between depres-
sion caseness and timepoint between during- and post-
lockdown was not statistically significant, suggesting that
both depression and no depression groups showed a
similar rate of decline in sleep duration between these
timepoints.
Discussion
In this study, we investigated the depressive symptom
trajectories for a cohort of adults with a recent history of
Fig. 2 Mean RSES score trajectories by depression caseness, as estimated from the repeated measures mixed model
Fig. 1 Mean PHQ-8 score trajectories by depression caseness, as estimated from the repeated measures mixed model
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MDD. For the sample as a whole, we found no evidence
that depressive symptoms or self-esteem changed over
the course of lockdown. However, we found evidence
that mean sleep duration decreased between during- and
post- lockdown. We also found that, relative to those
who did not show evidence of clinically relevant depres-
sive symptom severity shortly before the pandemic,
those with pre-pandemic depression showed a significant
decrease in sleep duration (in minutes) between pre-
and during- lockdown. However, while there were also
reductions in symptom and self-esteem scores, this re-
duction was not clinically meaningful.
The Covid-19 pandemic represents a unique health,
social and economic challenge, with the impact on
global mental health expected to be high [33], the use
of RMT to explore a pre-existing MDD cohort has
provided unique insights into behaviours over the
duration of the pandemic. The rapid spread and per-
sistence of Covid-19 has increased health anxieties,
and has resulted in an increase in mental health dis-
orders globally [34]. In our study, we focused on a
less studied area, those with pre-existing MDD, which
has been shown to be negatively impacted as a result
of the Covid-19 pandemic, with the severity varying
based on occupation, gender, geographical location
and physical/mental health comorbidities [33, 35, 36].
There are major differences in the prevalence of de-
pression globally, with one US cohort identifying a
three-fold increase in depression symptoms during
the pandemic than before [35]. This contrasts a
Dutch study, which found that while those with de-
pression scored highly on symptom scales, they did
not report greater increases in symptoms during the
pandemic [37].
Our overall findings are similar to those reported in
The Netherlands, while overall depression score changed
compared with a period just before the pandemic, the
change was not clinically meaningful and suggests par-
ticipants depression remained stable. It is important to
acknowledge that lockdown restrictions could have
moderated depression symptom change, with varying
levels of restrictions imposed across the UK, The
Netherlands and Spain. In addition, our findings could
be explained as regression to the mean, or improve-
ments in depression over time due to the cyclic nature
of the disorder.
Sufficient sleep is essential for cognitive and psycho-
logical functioning, and prior research has shown that
poor quality sleep is associated with depression and lon-
ger term health outcomes [38–40]. Using data collected
via a wearable device and RMT, we found that trajector-
ies of sleep duration decreased significantly pre-, during-
and post-lockdown in the depressed group with evidence
of an interaction between pre- and during- lockdown.
This reduction in sleep, and persistence to post-
lockdown could indicate an adverse impact of the pan-
demic and requires further investigation to assess its im-
pact on clinical outcomes. An alternative theory could
be that reduced activity levels could result in less sleep
being required, and not, therefore, detrimental but
merely an adjustment in how much sleep is needed. It
must be acknowledged that prior research has indicated
that FitBit devices underestimate sleep onset, which
could have impacted our results [41].
Fig. 3 Mean sleep duration (in minutes) trajectories by depression caseness, as estimated from the repeated measures mixed model
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Self-esteem is an important indicator of self-worth.
When a participant has healthy self-esteem, they tend to
feel positive about themselves, and about life in general.
Conversely, when self-esteem is low, participants tend to
see themselves and life in a more negative and critical
light [27, 29, 42]. In this study, we found that there were
differences in self-esteem across timepoints, with small
but not clinically meaningful changes between pre-, and
during- lockdown. This could suggest an overall small
change in the outlook of participants with pre-pandemic
depression.
Our study demonstrates the utility of RMT and wear-
able technology to evaluate the impact of Covid − 19.
The potential to gather high-frequency information via
wearable technology and smartphones using platforms
such RADAR-MDD project has advantages over mo-
mentary data capture currently employed in a clinical
setting, which often presents in the form of infrequent
questionnaires. The capacity of RMT to offer passive
monitoring, without the need for active participant en-
gagement, allows longitudinal assessment of more ob-
jectively collected outcomes as well as the capacity to
offer multi-parametric monitoring. The results of this
work enhance our understanding of the impact of lock-
down due to Covid − 19 for those with MDD as moni-
tored through RMT.
The Covid-19 pandemic presents a unique opportunity
for deploying RMT to track disease progression or re-
lapse in symptoms, despite the global lockdown and fre-
quent local restrictions. This works demonstrates the
application of large-scale multi-parametric monitoring,
gathered at an incomparable frequency to once-off clinic
visits, providing real-time data on the effects of Covid-19
for those with MDD and their environment. The unique
strength of this work is the ability to directly compare
results gathered during- and post-lockdown with previ-
ously collated shortly before the start of the pandemic.
Many studies rely on participant recall of pre-pandemic
health and well-being statuses for comparison purposes.
The nature of this study avoids potential recall bias, in
addition to the fact that symptom changes are tracked at
a high frequency and responses are submitted in real-
time via a phone application. The original study aims
were not related to Covid − 19, and participants included
in these analyses joined before December 2019, which
allows for the elimination of lockdown bias; participants
were not motivated to take part simply on the basis of
being personally affected by the pandemic.
Notwithstanding these strengths, our study does have
some limitations. First, technical issues with mobile de-
vices and RMT apps could have impacted data collection
and have contributed to missing data. In addition, par-
ticipant adherence to the study protocol (ie. question-
naire completions) decreases over time which further
contributes to missing data. While it is difficult to over-
come these issues, it is more reflective of real-world data
collection and future work will explore if missing data,
in itself, is an informative indicator of the participant’s
current state. In addition, the pandemic has placed
unique stressors on individuals which may have further
contributed to data completes. For example, some par-
ticipants may have been more adherent to the RADAR-
MDD project due to fewer life distractions, whereas in
some life could have become very difficult resulting in
less adherence. Future research should seek to explore
this further. Second, RADAR-MDD project used a range
of recruitment strategies across the different sites includ-
ing self-enrolment registers and clinical services, there-
fore the sample is not necessarily representative of the
wider population with MDD. Third, when assessing
sleep duration, this study only considered those who
slept during the night and not those who had daytime
sleep duration. Further work should be undertaken to
explore differences between daytime sleep and night-
time sleep duration.
Global healthcare systems face unprecedented chal-
lenges in meeting the unmet mental health need. The ef-
fects of this pandemic will undoubtedly have far-
reaching consequences, with potential long and short-
term psychological impacts. However, the results of this
study suggest that those with MDD do not experience a
significant worsening in symptoms during the first
months of the Covid − 19 pandemic. Future work should
attempt to examine the association between individual
socio-demographic characteristics and changes in the
examined variables, notable prior to the pandemic and
within an individual, to further unpick the impact on
those with MDD.
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